SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer

NCT04977024 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

63

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19 Infection
Hematopoietic and Lymphoid System Neoplasm
Leukemia
Lymphoma
Plasma Cell Myeloma

Interventions

BIOLOGICAL: COVID-19 Vaccine
OTHER: Diagnostic Laboratory Biomarker Analysis
BIOLOGICAL: Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1

Sponsor

GeoVax, Inc.